Lyse Moves to the Cloud with CSG to Enhance Mobile Customer Experience
Lyse, one of Norway's largest energy and telecommunication companies, is a pioneer in customer-focused innovation. To wow customers and deliver effortless experiences for generations to come, Lyse chose CSG®’s (NASDAQ: CSGS) cloud-native, software-as-a-service (SaaS) platforms to modernise its mobile consumer business. This move to the cloud enables Lyse to consolidate offerings, strategically complement services and boost business growth with long-term cost-effectiveness. With a vision towards the future, Lyse is poised to raise the bar for customer experience in the Norwegian telecommunications market.
“As the digital landscape rapidly evolves, we are committed to keeping our customers at the heart of our evolution,” said Jan-Erik Hvidsten, SVP of Technology, Lyse. “Partnering with CSG is a pivotal step in our journey to revolutionise our service offerings and expand our reach across markets. By leveraging CSG’s advanced SaaS solutions, we are confident in our ability to scale the business as we grow and deliver unparalleled value to our mobile customers for generations to come. Together, we will make a difference.”
Lyse will accelerate its growth with agility and intelligence by leveraging CSG Ascendon, a market-leading AWS cloud-native revenue management platform, and CSG’s pre-integrated, world-class customer engagement capabilities. With CSG’s end-to-end solutions, Lyse can easily bring offerings together, adapt to the unique needs of each user in real-time and deliver customer journeys that elevate the brand experience. These improvements lead to effortless customer self-service across all touchpoints and make it easy for the consumer to recognise the value in the services they are buying.
“Leading service providers like Lyse face an increasingly complex and competitive market,” said Daniel Kjellander, VP of Nordics at CSG. “To thrive and be future-ready, they need comprehensive cloud solutions that streamline their operations and improve customer engagement through contextual personalisation. By making subscription payment effortless for its customers, Lyse is creating customer loyalty that leads to faster revenue. CSG is proud to be on this evolutionary journey with Lyse and provide the future-forward cloud solutions they need to elevate customer experience.”
Get the facts on CSG Ascendon’s B2C, B2B and B2B2X capabilities and hear from Forrester on why CSG Xponent is a good fit for big brands looking for industry-tailored maturity models, deep data capabilities and journey-based AI products.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.
Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.
About Lyse
Lyse is a Norwegian energy and telecom company. Lyse builds, maintains and upgrades critical infrastructure and delivers broadband and entertainment services through our national Altibox partnership. Our telecom services are delivered through our national brands: Altibox, Ice and NiceMobil.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806091476/en/
Contacts
CSG
Kristine Østergaard
Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com
John Rea
Investor Relations
+1 (210) 687-4409
john.rea@csgi.com
Lyse
Andreas Veggeland
Public Relations
+47 982 96 708
andreas.veggeland@lyse.no
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom